ArticleFrontiers in medicine2026
Survival outcomes of spleen-strengthening and dampness-eliminating traditional Chinese medicine granules combined with lenvatinib for unresectable hepatocellular carcinoma: a large-sample retrospective study based on electronic medical records.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lenvatinib has been proven as a first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Traditional Chinese Medicine (TCM), particularly formulations targeting spleen strengthening and dampness elimination, has the potential for synergistic effects with targeted therapies. Researchers conducted a study to investigate the feasibility of combining spleen-strengthening and dampness-eliminating TCM granules with lenvatinib to improve survival rates in patients with unresectable HCC. Methods: This is a single-center retrospective cohort study that examined electronic medical records from one of the Beijing Royal Integrative Medicine Hospital between January 2023 and December 2025. Patients with unresectable HCC who received lenvatinib treatment as first-line therapy were divided into a combination group (TCM granules combined with lenvatinib, Results: Following 1:1 PSM, 156 patients were enrolled in each group. The combination group had a significantly longer median OS compared with the control group (18.7 months vs. 14.2 months; HR = 0.68, 95% CI: 0.52-0.89, Conclusions: Adjunctive therapy with spleen-strengthening and dampness-eliminating TCM granules was associated with better survival outcomes and fewer adverse events in patients with unresectable HCC receiving lenvatinib. These findings provide a rationale for prospective trials evaluating the integration of TCM into modern oncological treatment paradigms for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.